Bright Mountain Media to Host Virtual Roadshow Webinar on July 1st, 2020 at 11:30 A.M. Eastern Time

Written by Customer Service on June 18, 2020. Posted in Public Companies.

Boca Raton, FL, June 18, 2020 (GLOBE NEWSWIRE) — Bright Mountain Media, Inc. (OTCQB: BMTM) (“Bright Mountain Media” or the “Company”), an end-to-end digital media and advertising services platform, today announced that it will host a virtual roadshow webinar on July 1st, 2020 at 11:30 a.m. Eastern time.Greg Peters, President and Chief Operating Officer of Bright Mountain Media, will present an overview of the business model and discuss recent growth initiatives, including the recent acquisition of Wild Sky Media. The webinar will be accompanied by a presentation and followed by a question and answer session, which can be accessed via the webcast link or dial-in numbers below.To access the webinar, please use the following information:Date: Wednesday, July 1st, 2020Time: 8:30 a.m. Pacific time (11:30 a.m. Eastern time) Dial-in:...

Swiss Water Announces Retirement of Chairman and Appointment of New Director

Written by Customer Service on June 18, 2020. Posted in Public Companies.

VANCOUVER, British Columbia, June 18, 2020 (GLOBE NEWSWIRE) — Swiss Water Decaffeinated Coffee Inc. (TSX – SWP) (“Swiss Water” or “the company”) today reported that David Rowntree has announced his intention to retire as Chairman and Director of the company immediately following Swiss Water’s 2020 annual general meeting of shareholders (AGM) on June 25, 2020. Mr. Rowntree has served as Chairman since the company went public in 2002. “On behalf of the board and management of Swiss Water, I want to thank David Rowntree for his invaluable contribution to the company over the past 18 years,” said Frank Dennis, President, CEO and a Director of Swiss Water. “On a personal note, I would also like to express my appreciation to David for his guidance and mentorship. As Chairman, his insights and even-handed management of all board business,...

QIWI Announces 2020 Annual General Meeting

Written by Customer Service on June 18, 2020. Posted in Public Companies.

NICOSIA, Cyprus, June 18, 2020 (GLOBE NEWSWIRE) — QIWI plc (Nasdaq: QIWI), (MOEX: QIWI) (“QIWI” or the “Company”) today announced that its 2020 annual general meeting of shareholders (the “AGM”) will be held on Tuesday August 4, 2020, at 10:00 a.m. (Cyprus time) at 12 Kennedy Avenue, Kennedy Business Centre, 2nd floor, 1087, Nicosia, Cyprus.Only shareholders of record at the close of business on June 17, 2020 are entitled to receive notice and to vote at the AGM and any adjourned meeting thereof. Holders of the Company’s American Depositary Shares (the “ADS”) who wish to exercise their voting rights for the underlying shares must act through the depositary of the Company’s ADS program, The Bank of New York Mellon. Shareholders are cordially invited to attend the AGM.At...

Golden Tag Announces Tom English Joins Board of Directors

Written by Customer Service on June 18, 2020. Posted in Public Companies.

TORONTO, June 18, 2020 (GLOBE NEWSWIRE) — Golden Tag Resources Ltd. (“Golden Tag” or the “Company“) (TSX.V: GOG) has appointed Tom English to the Company’s Board of Directors. Mr. English has over 20 years of experience in the financial industry and has held numerous senior roles at investment banks including CIBC World Markets and Salman Partners. Mr. English has provided financial solutions for both small and large cap companies across all business sectors. During his career he has been involved in transactions across the entire capital structure, including financings (debt, equity, IPO) and mergers and acquisition advisory assignments.Greg McKenzie, President and CEO commented, “We would like to welcome Mr. English to the Golden Tag team as a Director of the Company. His years of extensive capital market...

Altus Group Announces Second Quarter 2020 Dividend

Written by Customer Service on June 18, 2020. Posted in Public Companies.

TORONTO, June 18, 2020 (GLOBE NEWSWIRE) — Altus Group Limited (“Altus Group” or “the Company”) (TSX: AIF), a leading provider of software, data solutions and independent advisory services to the global commercial real estate industry, announced today that the Board of Directors has approved the payment of a cash dividend of $0.15 per common share for the second quarter ending June 30, 2020. Payment will be made on July 15, 2020 to common shareholders of record as at June 30, 2020.Altus Group’s Dividend Reinvestment Plan (“DRIP”) permits eligible shareholders to direct their cash dividends to be reinvested in additional common shares of the Company. For shareholders who wish to reinvest their dividends under the DRIP, Altus Group intends to issue common shares from treasury at a price equal to 96% of the weighted average closing...

Frestun fundar skuldabréfaeigenda – KLS 13 1

Written by Customer Service on June 18, 2020. Posted in Public Companies.

Með vísan til fréttatilkynningar þann 11. júní síðastliðinn þar sem boðað var til fundar föstudaginn 19. júní. Ákveðið hefur verið að fresta tilgreindum fundi meðal skuldabréfaeigenda KLS 13 1 og verður boðað til nýs fundar í viku 26 með nýrri fréttatilkynningu.Frekari upplýsingar veitir Anna Kristjánsdóttir (anna.kristjansdottir@stefnir.is) forstöðumaður skuldabréfa hjá Stefni hf.

PRA Health Sciences针对《RACE法案》的儿科肿瘤相关要求已做好准备

Written by Customer Service on June 18, 2020. Posted in Public Companies.

北卡罗来纳州罗利市, June 19, 2020 (GLOBE NEWSWIRE) — 2007-2017年间，美国食品药品管理局批准了78种新型成人癌症药物，1 但其中没有任何一种药物完成了旨在确定其针对儿科癌症功效的研究。这种情况将在8月18日《RACE法案》（《加快儿童治疗和平等法案》）生效后发生变化。2017年通过的《RACE法案》修正了现有《PREA》，即：《儿科研究平等法案》，并取消了癌症用途孤儿药的PREA要求豁免。这部新法要求对用于治疗成人癌症且其分子靶点与儿科肿瘤生长或发展密切相关的新药物和生物制品进行儿科评估。临床研究企业及其儿科研究专家（包括PRA Health Sciences）将被要求为主办所需儿科肿瘤指标研究的制药和生物技术公司提供支持。PRA Health Sciences儿科临床开发中心的Mark Sorrentino博士表示：“现在距《RACE法案》生效仅有60天的时间，因此各方都在争相制定肿瘤学研究的儿科研究方案。” “在PRA，我们自2017年《RACE法案》通过以后就一直在做准备，从而可以快速有效地支持我们的客户和主办方进行这项研究。我们组建了一支具备极高资质的内部团队，作为开发和执行儿科研究方案的实践顾问。”PRA儿科临床开发中心和《RACE法案》执行团队成员包括Sorrentino博士、Martine Dehlinger-Kremer博士（科学事务副总裁，儿科主题专家）、高级儿科战略联系人Jacqui Whiteway博士、Jo Dewhurst（LLB Dip）以及儿科战略联系人Missy Hansen（MSN、APRN、CNP-儿科）。加上新增的数十名其他PRA研究人员和儿科专家，这一专职的专家组已做好准备，利用在儿科临床开发方面的共同经验，支持以《RACE法案》为核心的各项计划。 Dehlinger-Kremer博士表示：“父母和儿科肿瘤学家需要获得信心，能够信任他们为孩子提供的疗法和药物对于儿科患者对抗癌症均安全且有效。”...

PRA Health Sciences 準備深入了解《RACE 法案》對兒科腫瘤學的要求

Written by Customer Service on June 18, 2020. Posted in Public Companies.

北卡羅萊納州拉里市, June 19, 2020 (GLOBE NEWSWIRE) — 在 2007 年至 2017 年之間，美國食品及藥物監督管理局 (FDA) 共批准了 78 種新的成年癌症藥物，1 但這些藥物均未進行旨在確定其對兒科癌症藥效的研究。這種情況將在《RACE 法案》（即兒童研究平等法案）於 8 月 18 日生效時發生變化。《RACE 法案》於 2017 年通過，對現時稱為 PREA 的《兒童研究公平法案》作出了修訂，並對被列為孤兒藥物的癌症藥物取消《PREA 法案》豁免。根據新法例，旨在治療成人的癌症新藥及生物製劑，以及與兒科癌症生長或進展基本上相關的分子標靶治療，均必需進行兒科評估。臨床研究公司及其兒科研究專家，當中包括 PRA Health Sciences，將被要求支援製藥和生物技術公司，因為它們贊助兒科腫瘤適應症的相關必要研究。PRA Health Sciences 兒科臨床發展中心副總裁 Mark Sorrentino 醫生說：「我們距離《RACE 法案》生效有 60 天，而這項要求為製定腫瘤學的兒科研究計劃帶來了一點挑戰。在 PRA，我們自《RACE 法案》於 2017 年通過以來一直盡力做好預備工作，因此我們能夠快速而有效地支持希望進行這項研究的客戶和贊助商。我們已在內部召集了一支資歷甚高的團隊，在兒童研究計劃的制訂和執行方面擔任前線顧問。」PRA 的兒科臨床發展中心和負責實施《RACE 法案》的團隊包括 Sorrentino 醫生以及兒科專家科學事務副總裁 Martine Dehlinger-Kremer 醫生、高級兒科策略聯絡主任 Jacqui Whiteway 醫生、持有法學學士文憑的 Jo Dewhurst 醫生，以及具備 MSN 護士、高級執業註冊護士、兒科認證執業護士資格的兒科策略聯絡主任 Missy Hansen。這些專門的專家團隊共同努力，再加上數十名其他 PRA 研究人員和兒科專家，現已隨時準備就緒利用在兒科臨床開發方面的集體經驗來合力支持專於《RACE...

PRA Health Sciences prête à satisfaire les exigences du RACE Act pour l’oncologie pédiatrique

Written by Customer Service on June 18, 2020. Posted in Public Companies.

RALEIGH, Caroline du Nord, 18 juin 2020 (GLOBE NEWSWIRE) — Entre 2007 et 2017, 78 nouveaux agents anticancéreux chez les adultes ont été approuvés par la Food and Drug Administration des États-Unis,1 mais aucun de ces médicaments n’a fait l’objet de recherches afin de déterminer son efficacité pour les cancers pédiatriques.Cela va changer le 18 août lorsque le RACE Act (Research to Accelerate Cures and Equity for Children Act ou Loi sur la recherche visant à accélérer les traitements et l’équité pour les enfants) entrera en vigueur. Adopté en 2017, le RACE Act modifie le Pediatric Research Equity Act (PREA ou Loi sur l’équité des recherches pédiatriques) et supprime l’exemption prévue par le PREA pour les médicaments anticancéreux qui ont le statut d’orphelin. La nouvelle loi exige une évaluation...

PRA Health Sciences ist bereit, die Anforderungen des RACE Act für die pädiatrische Onkologie zu erfüllen

Written by Customer Service on June 18, 2020. Posted in Public Companies.

RALEIGH, North Carolina, USA, June 18, 2020 (GLOBE NEWSWIRE) — Zwischen 2007 und 2017 wurden 78 neue Krebsmittel für Erwachsene von der US-amerikanischen Food and Drug Administration zugelassen,1 jedoch wurde keines dieser Arzneimittel im Hinblick auf seine Wirksamkeit bei pädiatrischen Krebserkrankungen untersucht.Dies wird sich am 18. August ändern, wenn der RACE Act – der Research to Accelerate Cures and Equity for Children Act (das Gesetz über Forschung zur Beschleunigung von Heilung und Gleichstellung von Kindern) – in Kraft tritt. Der 2017 verabschiedete RACE Act ergänzt das bereits bestehende PREA-Gesetz (Pediatric Research Equity Act) und hebt die Befreiung von den PREA-Anforderungen für Krebsmedikamente auf, die Orphan-Drug-Status haben. Das neue Gesetz schreibt die pädiatrische Untersuchung neuer Arzneimittel und Biologika...

Day: June 18, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice